🇺🇸 FDA
Pipeline program

LVIVO-TaVec200 product

LB2503-0001

Phase 1 mab active

Quick answer

LVIVO-TaVec200 product for Multiple Myeloma is a Phase 1 program (mab) at First Tracks Biotherapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
First Tracks Biotherapeutics
Indication
Multiple Myeloma
Phase
Phase 1
Modality
mab
Status
active

Clinical trials